Published in Br J Cancer on January 01, 1997
Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer (1999) 0.99
A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer (2008) 0.92
CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract. Eur J Nutr (2011) 0.81
Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy. J Control Release (2014) 0.80
ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. Clin Cancer Res (2015) 0.80
Promotion of microtubule assembly in vitro by taxol. Nature (1979) 12.73
Features of apoptotic cells measured by flow cytometry. Cytometry (1992) 6.45
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol (1994) 1.79
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood (1991) 1.56
Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res (1991) 1.36
Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res (1987) 1.33
Crystal and molecular structure of paclitaxel (taxol). Proc Natl Acad Sci U S A (1995) 1.25
Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res (1984) 1.23
Taxol: a new and effective anti-cancer drug. Anticancer Drugs (1991) 1.17
Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res (1990) 1.16
Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst (1993) 1.13
Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry (1996) 1.10
Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer (1995) 1.05
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res (1994) 1.03
Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer (1988) 0.99
Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother Pharmacol (1991) 0.98
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer (1989) 0.93
Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia (1994) 0.93
Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res (1990) 0.84
Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur J Cancer (1992) 0.83
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol (1988) 3.92
Effect of a nicotine-free inhalator as part of a smoking-cessation programme. Eur Respir J (2011) 3.25
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause (2000) 2.27
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol (2010) 2.27
Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis (2008) 2.19
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy. Sex Transm Dis (1998) 1.87
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol (2002) 1.82
In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother Pharmacol (2000) 1.77
Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer (2007) 1.72
A telemedicine support for diabetes management: the T-IDDM project. Comput Methods Programs Biomed (2002) 1.69
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer (1996) 1.66
Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65
Sonographic features of decidualized ovarian endometriosis suspicious for malignancy. Ultrasound Obstet Gynecol (2004) 1.62
An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. J Clin Pharm Ther (1998) 1.59
Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. J Immunol (1999) 1.55
Activity of bilobalide, a sesquiterpene from Ginkgo biloba, on Pneumocystis carinii. Antimicrob Agents Chemother (1993) 1.54
Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol (1996) 1.49
Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit Care Med (2001) 1.48
Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. Fertil Steril (1995) 1.47
Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Hum Reprod (2011) 1.46
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer (2006) 1.46
Inflammatory myofibroblastic tumor (inflammatory pseudotumor): DNA flow cytometric analysis of nine pediatric cases. Cancer (1996) 1.45
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer (1995) 1.44
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol (2007) 1.44
Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol (2005) 1.43
Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors. Br J Haematol (1997) 1.42
Cisplatin and vinorelbine as neoadjuvant chemotherapy in locally advanced cervical cancer: a phase II study. Int J Gynecol Cancer (2003) 1.41
Complete response to pre-operative chemotherapy in stage III B cervical carcinoma. Case report. Br J Obstet Gynaecol (1988) 1.37
Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J Ultrasound Med (1992) 1.37
Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer (1997) 1.33
Spatiotemporal dynamics of the electrical network activity in the root apex. Proc Natl Acad Sci U S A (2009) 1.32
Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol (1992) 1.31
[Intramedullary pinning of diaphyseal fractures of both forearm bones in adults: 46 cases]. Rev Chir Orthop Reparatrice Appar Mot (2008) 1.28
Protocol-based reasoning in diabetic patient management. Int J Med Inform (1999) 1.28
GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer (2001) 1.27
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology (2000) 1.26
Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med (2006) 1.24
ASPicDB: a database resource for alternative splicing analysis. Bioinformatics (2008) 1.23
A randomized study comparing retroperitoneal drainage with no drainage after lymphadenectomy in gynecologic malignancies. Gynecol Oncol (1997) 1.23
Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes. Scand J Immunol (1992) 1.22
Antibodies cytotoxic to bovine parathyroid cells in autoimmune hypoparathyroidism. Proc Natl Acad Sci U S A (1986) 1.21
Clostridium difficile toxin B induces apoptosis in intestinal cultured cells. Infect Immun (1998) 1.20
Mining biomedical time series by combining structural analysis and temporal abstractions. Proc AMIA Symp (1998) 1.20
Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate (2001) 1.18
Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer (1998) 1.18
Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer (2005) 1.17
Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood (1996) 1.16
Is chloromethyl-X-rosamine useful in measuring mitochondrial transmembrane potential? Cytometry (1998) 1.15
Surgery by minilaparotomy in benign gynecologic disease. Obstet Gynecol (1996) 1.15
Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol (2007) 1.15
HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol (2001) 1.14
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol (2000) 1.14
Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet (1980) 1.13
CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma (2002) 1.13
Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol (1990) 1.12
Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol (2002) 1.12
Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol (1997) 1.12
HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population. J Oral Pathol Med (1999) 1.10
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res (1999) 1.10
Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry (1996) 1.10
Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod (2001) 1.10
Stromal-epithelial interactions modulate estrogen responsiveness in normal human endometrium. Biol Reprod (2001) 1.09
Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol (1994) 1.08